Factors associated with thrombosis in Behçet Syndrome: A systematic review and meta-analysis

IF 4.6 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism Pub Date : 2025-04-16 DOI:10.1016/j.semarthrit.2025.152736

Gul Guzelant-Ozkose , Berna Yurttas , Sinem Nihal Esatoglu , Muhlis Cem Ar , Vedat Hamuryudan , Gulen Hatemi

{"title":"Factors associated with thrombosis in Behçet Syndrome: A systematic review and meta-analysis","authors":"Gul Guzelant-Ozkose , Berna Yurttas , Sinem Nihal Esatoglu , Muhlis Cem Ar , Vedat Hamuryudan , Gulen Hatemi","doi":"10.1016/j.semarthrit.2025.152736","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Thrombosis is an important component of vascular involvement in Behçet syndrome (BS). Inflammation seems to be the main cause, while the contribution of factors associated with thrombosis is debated.</div></div><div><h3>Methods</h3><div>We searched PubMed and EMBASE for studies that assessed factors associated with thrombosis in patients with BS. We separately analyzed studies that compared BS patients with thrombosis to BS patients without thrombosis and studies that compared BS patients with thrombosis to non-BS patients with thrombosis. The pooled odds ratios with 95%CI were calculated for binary outcomes and standardized mean differences were calculated for continuous outcomes.</div></div><div><h3>Results</h3><div>A total of 87 factors were compared between BS patients with thrombosis and BS patients without thrombosis in 101 studies. Having a Factor V Leiden mutation increased the risk of thrombosis 2.58 times (95% CI 1.76 to 3.78) among patients with BS. Homocysteine levels and factor VIII levels were also significantly higher among BS patients with thrombosis. There were only 6 studies including 14 factors that compared BS patients with thrombosis to non-BS patients with thrombosis. The frequencies of JAK-2 mutation, activated protein C resistance, levels of tissue plasminogen activator (tPA) and activity of tPA were significantly higher among non-BS patients with thrombosis.</div></div><div><h3>Conclusion</h3><div>Prothrombotic factors do not seem to be the main driver of thrombosis in BS, but may pose an additional risk when present. Screening BS patients with thrombosis for common prothrombotic factors may be reasonable, especially in patients with unusual clinical and demographic features for vascular involvement of BS.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152736"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017225001076","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Thrombosis is an important component of vascular involvement in Behçet syndrome (BS). Inflammation seems to be the main cause, while the contribution of factors associated with thrombosis is debated.

Methods

We searched PubMed and EMBASE for studies that assessed factors associated with thrombosis in patients with BS. We separately analyzed studies that compared BS patients with thrombosis to BS patients without thrombosis and studies that compared BS patients with thrombosis to non-BS patients with thrombosis. The pooled odds ratios with 95%CI were calculated for binary outcomes and standardized mean differences were calculated for continuous outcomes.

Results

A total of 87 factors were compared between BS patients with thrombosis and BS patients without thrombosis in 101 studies. Having a Factor V Leiden mutation increased the risk of thrombosis 2.58 times (95% CI 1.76 to 3.78) among patients with BS. Homocysteine levels and factor VIII levels were also significantly higher among BS patients with thrombosis. There were only 6 studies including 14 factors that compared BS patients with thrombosis to non-BS patients with thrombosis. The frequencies of JAK-2 mutation, activated protein C resistance, levels of tissue plasminogen activator (tPA) and activity of tPA were significantly higher among non-BS patients with thrombosis.

Conclusion

Prothrombotic factors do not seem to be the main driver of thrombosis in BS, but may pose an additional risk when present. Screening BS patients with thrombosis for common prothrombotic factors may be reasonable, especially in patients with unusual clinical and demographic features for vascular involvement of BS.

Abstract Image

查看原文本刊更多论文

behaperet综合征中与血栓形成相关的因素：一项系统回顾和荟萃分析

目的血栓形成是behet综合征（BS）血管受累的重要组成部分。炎症似乎是主要原因，而与血栓相关的因素的贡献是有争议的。方法：我们检索PubMed和EMBASE中评估BS患者血栓形成相关因素的研究。我们分别分析了有血栓形成的BS患者与没有血栓形成的BS患者的比较研究，以及有血栓形成的BS患者与没有血栓形成的BS患者的比较研究。二元结果计算95%CI的合并优势比，连续结果计算标准化平均差异。结果101项研究中，有血栓形成的BS患者与无血栓形成的BS患者共87项因素进行了比较。在BS患者中，Leiden因子V突变使血栓形成的风险增加2.58倍（95% CI 1.76 - 3.78）。BS合并血栓患者的同型半胱氨酸水平和因子VIII水平也显著升高。仅有6项研究包括14项因素对BS合并血栓患者与非BS合并血栓患者进行了比较。JAK-2突变频率、活化蛋白C耐药、组织纤溶酶原激活物（tPA）水平及tPA活性在非bs合并血栓患者中显著升高。结论血栓形成前因素似乎不是BS患者血栓形成的主要驱动因素，但存在时可能会增加血栓形成的风险。对伴有血栓形成的BS患者进行常见的血栓前因子筛查可能是合理的，特别是在BS血管累及的临床和人口学特征不寻常的患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in arthritis and rheumatism 医学-风湿病学

CiteScore

9.20

自引率

4.00%

发文量

176

审稿时长

46 days

期刊介绍： Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.